Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01182350 · BASELINE

Baseline characteristics

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) · Source last updated 2019-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      50
    units
    Participants
groups
  1. description
    Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days). Treatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O\^6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).
    id
    BG000
    title
    All Biopsied Participants
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          3.3
          upper Limit
          17.5
          value
          6.3
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          27
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          23
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          50
      title
      United States
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Region of Enrollment
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          30
        title
        MGMT-/EGFR-
      2. measurements
        1. group Id
          BG000
          value
          14
        title
        MGMT-/EGFR+
      3. measurements
        1. group Id
          BG000
          value
          3
        title
        MGMT+/EGFR-
      4. measurements
        1. group Id
          BG000
          value
          3
        title
        MGMT+/EGFR+
    description
    Treatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O\^6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Molecular Classification
    unit Of Measure
    Participants
population Description
The analysis dataset is comprised of all enrolled participants who underwent stereotactic biopsy.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      50
    units
    Participants
groups
  1. description
    Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days). Treatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O\^6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).
    id
    BG000
    title
    All Biopsied Participants
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          3.3
          upper Limit
          17.5
          value
          6.3
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          27
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          23
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          50
      title
      United States
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Region of Enrollment
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          30
        title
        MGMT-/EGFR-
      2. measurements
        1. group Id
          BG000
          value
          14
        title
        MGMT-/EGFR+
      3. measurements
        1. group Id
          BG000
          value
          3
        title
        MGMT+/EGFR-
      4. measurements
        1. group Id
          BG000
          value
          3
        title
        MGMT+/EGFR+
    description
    Treatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O\^6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Molecular Classification
    unit Of Measure
    Participants
population Description
The analysis dataset is comprised of all enrolled participants who underwent stereotactic biopsy.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice